La bourse ferme dans 5 h 5 min

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE Prix différé. Devise en USD
Ajouter à la liste dynamique
227,31+11,06 (+5,11 %)
À la clôture : 04:00PM EDT
227,25 -0,06 (-0,03 %)
Avant Bourse : 04:09AM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Secteur(s)Healthcare
Secteur d’activitéDiagnostics & Research
Employés à temps plein20 400

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. James C. Foster J.D.CEO, President & Chairman2,66MS.O.1951
Ms. Flavia H. PeaseCorporate Executive VP & CFO1,66MS.O.1973
Ms. Birgit GirshickCorporate Executive VP & COO1,28M464,88k1970
Mr. Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy928,36k262,98k1974
Mr. William D. BarboCorporate Executive Vice President of Community Relations1M399,92k1961
Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting OfficerS.O.S.O.1977
Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerS.O.S.O.S.O.
Mr. Mark MintzCorporate Senior VP & Chief Information OfficerS.O.S.O.S.O.
Todd SpencerCorporate Vice President of Investor RelationsS.O.S.O.S.O.
Mr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerS.O.S.O.S.O.
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Charles River Laboratories International, Inc. en date du 1 juillet 2024 est 6. Les scores principaux sont Audit : 6; Société : 5; Droits des actionnaires : 8; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.